Gold Co. Completes Five Diamond Drill Holes
Source: Ben Pirie 08/13/2024
Endurance Gold Corp (EDG:TSX.V) has reported consistently stellar drill results, according to an Atrium Research report.
Atrium Research analysts Ben Pirie and Nicholas Cortellucci, in a research report published on August 13, 2024, provided an update on Endurance Gold Corp (EDG:TSX.V) following the company’s announcement of progress on its 10,000m diamond drill program at the Reliance Gold Project. The analysts maintained their Buy rating and target price of CA$0.50 on the stock.
Endurance Gold reported completing five diamond drill holes totaling 1,854m as part of its ongoing 2024 drill program.
The analysts noted, “Assays are expected to start rolling in late August or early September.” They added, “To date, the five holes completed since early July combine for a total of 1,854m drilled. The holes are aimed at targeting the zone at depth with the average hole being ~370m in length, testing the northwestern extension of the Royal Shear.”
Pirie and Cortellucci highlighted the expansion of the Imperial Zone, stating, “These holes have expanded the Imperial Zone at depth and to the northwest by ~100m, growing the zone materially.”
They expressed optimism about the upcoming results, commenting, “We remind readers of the consistently stellar drill results EDG has reported over its history, and we expect these high-grade results to continue in this program.”
The analysts also noted ongoing work to refine the geological model for an inaugural mineral resource estimate and additional exploration activities at the Olympic Target area and Upper Eagle area.
Endurance Gold’s strategic focus includes advancing the Reliance Gold Project towards resource definition while continuing exploration to expand known mineralization and identify new targets. The company recently closed a CA$4.0 million private placement, with Director Richard Gilliam subscribing for the entire offering.
Pirie and Cortellucci highlighted recent insider buying, noting, “CEO Robert Boyd continues to buy on the open market with 60,000 shares totaling $8,475 being bought in 2024. This is in addition to the ~187,000 shares he bought in H2/23.” They added, “We believe this speaks to management’s confidence in the project and the big discount the shares are currently trading at.”
Atrium Research’s valuation methodology for Endurance Gold is not explicitly stated in the provided excerpt. However, the analysts maintain a target price of CA$0.50 per share, representing a potential return of 257% from the price at the time of the report of CA$0.14.
With a Buy rating and a target price of CA$0.50, Atrium Research sees significant upside potential for Endurance Gold. The analysts conclude, “The pending news flow should act as a catalyst to reignite this tightly held stock.”
Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
Important Disclosures:
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
Disclosures for Atrium Research, Endurance Gold Corp., August 13, 2024
Analyst Certification Each authoring analyst of Atrium Research on this report certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated securities discussed (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in the research, (iii) to the best of the authoring analyst’s knowledge, she/he is not in receipt of material non-public information about the issuer, (iv) the analyst does not own common shares, options, or warrants in the company under coverage, and (v) the analysts adhere to the CFA Institute guidelines for analyst independence.
About Atrium Research Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. For further information on our team, please visit https://www.atriumresearch.ca/team.
General Information Atrium Research Corporation (ARC) has created and distributed this report. This report is based on information we considered reliable; we have not been provided with any material non-public information by the company (or companies) discussed in this report. We do not represent that this report is accurate or complete and it should not be relied upon as such; further any information in this report is subject to change without any formal or type of notice provided. Investors should consider this report as only one factor in their investment decisions; this report is not intended as a replacement for investor’s independent judgment. ARC is not an IIROC registered dealer and does not offer investment-banking services to its clients. ARC (and its employees) do not own, trade or have a beneficial interest in the securities of the companies we provide research services for and does not serve as an officer or Director of the companies discussed in this report. ARC does not make a market in any securities. This report is not disseminated in connection with any distribution of securities and is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. ARC does not make any warranties, expressed or implied, as to the results to be obtained from using this information and makes no express of implied warranties for particular use. Anyone using this report assumes full responsibility for whatever results they obtain. This does not constitute a personal recommendation or take into account any financial or investment objectives, financial situations or needs of individuals. This report has not been prepared for any particular individual or institution. Recipients should consider whether any information in this report is suitable for their particular circumstances and should seek professional advice. Past performance is not a guide for future results, future returns are not guaranteed, and loss of original capital may occur. Neither ARC nor any person employed by ARC accepts any liability whatsoever for any direct or indirect loss resulting from any use of its research or the information it contains. This report contains “forward looking” statements. Forward-looking statements regarding the Company and/or stock’s performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Such statements involve a number of risks and uncertainties such as competition, technology shifts, market demand and the company’s (and management’s) ability to correctly forecast financial estimates; please see the company’s MD&A “Risk Factors” Section for a more complete discussion of company specific risks for the company discussed in this report. ARC is receiving a cash compensation from Endurance Gold Corp. for 12-months of research coverage. ARC retains full editorial control over its research content. ARC does not have investment banking relationships and does not expect to receive any investment banking driven income. ARC reports are primarily disseminated electronically and, in some cases, printed form. Electronic reports are simultaneously available to all recipients in any form. Reprints of ARC reports are prohibited without permission. To receive future reports on covered companies please visit https://www.atriumresearch.ca/research or subscribe on our website. The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.
( Companies Mentioned: EDG:TSX.V, )
Source: https://www.streetwisereports.com/article/2024/08/13/gold-co-completes-five-diamond-drill-holes.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Lion’s Mane Mushroom Nootropic
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, But it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity.
Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins.
Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system.
Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome.
Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function.
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
![Report abuse](/img/report_abuse.png)